Bioavailability Studies
Amount of a substance that becomes available (reaches the target organ or systemic circulation) to an organism's body for bioactivity when introduced through ingestion, inhalation, injection, or skin contact. Rate of bioavailability depends on factors such as the type of the substance and the composition of diet.
By analyzing global market trends with data from 2012 and 2013 projections of compound annual growth rates (CAGRs) through 2018.The North American market is expected to reach around $79 billion in 2017 and is expected to raise at a 7.9% compound annual growth rate to nearly $108 billion in 2020.
- Bioavailability of Liposomes
- Prodrugs
- Oral drugs
- Therapeutic systems
- Liposomal drug delivery
Related Conference of Bioavailability Studies
Bioavailability Studies Conference Speakers
Recommended Sessions
- Advances in BABE
- Assessment of Bioequivalence
- BA/BE of Biologics & Biosimilars
- Bioavailability Studies
- Bioequivalence Protocols : In vivo/ In vitro studies
- Bioequivalence Studies
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Clinical Trials
- Contract Research Organizations
- Factors Affecting Bioavailability
- Managing BA/BE Studies
- Nutrient Bioavailability
- Pharma Clinical Trials
- Pharmaceutical Industry: Entrepreneurs Investment Meet
- Regulatory Requirements for Bioequivalence
- Significance of BA/BE Studies
- Study Designs